HERON THERAPEUTICS, INC.HRTX

Market cap
$303.15M
P/E ratio
Dec 31,
2011
Dec 31,
2012
Dec 31,
2013
Dec 31,
2014
Dec 31,
2015
Dec 31,
2016
Dec 31,
2017
Dec 31,
2018
Dec 31,
2019
Dec 31,
2020
Dec 31,
2021
Dec 31,
2022
Net loss-12-23-55-76-98-173-197-179-205-227-221-182
Stock-based compensation expense261181426313351504743
Depreciation and amortization------222333
Amortization of debt discount00533,000573,000624,000111111-
Amortization of debt issuance costs----------00
Amortization of premium (accretion of discount) on short-term investments------034-0-01
Realized gain on available-for-sale investments--------8,000---
Asset Impairment Charges---1---00100
Loss on disposal of property and equipment----0118,000-0-0-0-0--1-0
Accounts receivable0----24023-252-617
Inventory-----5529-141766
Prepaid expenses and other assets0-00020-0712-18-1
Accounts payable01-01751,000412-2-14-23-1
Increase Decrease In Clinical Liabilities---21814-41015-261
Accrued payroll and employee liabilities---024052-22-2
Other accrued liabilities---32211155-7-513
Net cash used in operating activities-8-17-41-60-78,526,000-134-170-192-125-185-203-147
Purchases of short-term investments--------477134129146
Maturities and sales of short-term investments------132228462350165144
Purchases of property and equipment112113397732
Proceeds from the sale of property and equipment----241,000-00--00
Net cash provided by (used in) investing activities-1-1-2-1-56,960,000158-279-2220933-3
Net proceeds from sale of common stock--5859----162--75
Proceeds from Convertible Debt-3--------149-
Proceeds from purchases under the Employee Stock Purchase Plan0000257,0001112221
Proceeds From Payments For Stock Issued Under The Equity Incentive Plan------------2
Net cash provided by financing activities2454616213857294358186915675
Net decrease in cash and cash equivalents--------4033-15-75
Interest paid------31--12